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Abstract  
Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers, but the influence of 
microRNA (miRNA) expression has only been sporadically analysed. We hypothesized that miRNAs are differ-
entially expressed in cSCC and hence influence its development. We therefore isolated total miRNA from 
well-differentiated cSCCs and from controls without SCC.  
Expression analyses of 12 miRNAs showed three significantly differentially expressed miRNAs. We identified 
a significant upregulation of the miR-21 and the miR-31, a proto-oncogene like miR-21. While the upregulat-
ed expression of miR-21 has been known for some time, the increased expression of miR-31 was never 
shown so clearly. Furthermore we showed the upregulation of miRNA-205, which has never been described 
before. The miR-205 induces specific keratinocyte migration and could be a characteristic marker for cSCC. It 
has to be determined in following studies whether these upregulated expressions are specific for cSCC and if 
so, for which cSCC-stages. 
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Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers and leading to death in 
0.5 to 2% of the cases in Europe (1-3). Numerous pathways are reported to be involved in its development, 
but the influence of microRNAs (miRNA) has only been sporadically analysed (4-7) and the relation between 
their expression and cSCC development has only scarcely been looked at (8, 9).  
We hypothesized that miRNAs are differentially expressed in cSCC and hence influence its development. We 
therefore isolated total RNA of 10 formalin-fixed and paraffin-embedded (FFPE) well-differentiated cSCCs 
from 9 immunocompetent individuals without inherited cancer predisposition. Additionally, a HPV analysis 
was performed (suppl. material). As a control, 11 total RNA samples were isolated from healthy epidermis 
from patients without SCC. The selected 12 miRNAs (Table S1) were previously reported to be differentially 
expressed in several types of cancer or are involved in epidermis differentiation (10-12). Normalization of 
miRNA expression was carried out against four different snoRNAs (U18, U24, U44, and U48) reported to be 
invariably expressed in skin (13). The study was approved by the local Ethics Committee of Basel and per-
formed according to the declaration of Helsinki. 
Expression analyses showed three significantly differentially expressed miRNAs (miR-21, miR-31, miR-205), 
which were all upregulated in cSCCs (Fig. S1). The normalization showed significant results for miR-21 and -31 
against all four snoRNAs whereas data for miR-205 was significant only relative to three snoRNAs (Fig. S2). 
Three miRNAs (miR-17-5p, 106a, -155) were significantly increased only when normalized against some 
snoRNAs (Fig. S3). A significant decrease was found in let-7b-5p when normalized against U44. Two miRNAs 
(miR-184 and -206) were detectable neither in the control skin nor in the cSCCs within a reliable cycle num-
ber of less than 40 cycles. HPV-DNA was not detectable in any cSCC sample. 
 
The oncogenic potential of miR-21 is well known and reported in many other cancers (14). The high induction 
of miR-21 in the well-differentiated cSCCs vs. normal skin confirms previously published data (8). Concurrent 
with our examinations an upregulation of miR-31 in cSCCs was reported (Table 1) (9). Like miR-21, miR-31 is a 
proto-oncogene (15), but its effect seems to be versatile in several cancers and cancer stages (16-20). In cSCC 
the function of miR-31 has yet to be clarified. 
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In contrast to previously published data on cSCCs the expression of miR-205 is increased in our samples when 
normalized to three snoRNAs (U18, U24, and U48) (Table 1, Fig S1) (8, 9). These different results may also be 
influenced by the method and normalization. Increased levels of miR-205 were shown in aggressive oral SCCs 
(21). Supporting a proto-oncogene function, miR-205 enhances the migration of keratinocytes in the cutane-
ous epidermis (22). Previous findings revealed that miR-205 is antagonized by miR-184 (21) which is in ac-
cordance with our results of an undetectable miRNA-184 level. Previous reports on the expression of miR-
184 diverge (8, 9).  
Our analyses showed no difference in the expression of miR-203 in cSCC and in normal skin, as also reported 
by Xu et al. 2012. In contrast, Dziunycz et al. 2010 reported this same miRNA to be downregulated in cSCC. 
The tumour-suppressor miR-203, a skin and keratinocytes-specific miRNA, mediates p63 degradation (11, 23-
25). This is in agreement with a decreasing expression of miR-203 with lower differentiation stage of the tu-
mour (8). As we aimed for examination of early and clearly well-differentiated cSCC and found no regulation 
of miR-203 expression, the miR-203 level could be an indicator for the differentiation grade of the tumour. 
Consistently, the expression of miR-34a, another tumour-suppressor downstream of p63, is not differentially 
regulated in our cSCC tissues.  
As reported previously and confirmed by our results, the choice of normalization genes has a strong impact 
on the results. The results show a clear involvement of several unsuspected miRNAs in cSCC development. As 
it is known for other cancers, we assume that the miR-levels change during carcinogenesis. This hypothesis 
could be tested by analysing actinic keratoses and all stages of cSCC. An expression signature of miRNA in 
different cSCCs could sharpen the individual prognosis of the metastatic risk. Finally, deeper understandig of 
differential miRNA expression in cSCC development may lead to the development of new and better targeted 
therapies (19). HPV is supposedly a risk factor for cSCC development. However, only half of cSCCs reveal HPV-
DNA (6, 26, 27) whereas no HPV-activity could be detected (28). Evidences show that HPV effects are boost-
ed during actinic keratosis (29).  
In conclusion, our results reveal new miRNA players in the carcinogenesis of cSCCs. Concurrent with Xu et al. 
we identified a significant upregulation of the miR-31 in well differentiated cSCCs. Furthermore we showed 
the differential upregulation of miRNA-205. Whether miR-205 has an influence on the development of cSCCs 
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must be clarified in subsequent studies. Significant increase of miR-21 in cSCC tissues could be confirmed by 
our observations. The question on which miRNAs are characteristically differentially expressed during cSCC 
development remains. For example, miR-21 is generally upregulated in proliferating tissues and miR-125a is 
downregulated in cutaneous non-tumourous proliferating tissues (30). In contrast, miR-205 induces 
keratinocyte migration (22) hence its expression level could be used as a specific marker for cSCCs develop-
ment. Whether miR-31 upregulation is specific for cSCCs, for other types of SCCs or for other cancers has yet 
to be determined in additional studies. Data of all stages from precancerous lesion to metastasize cSCC along 
with the clinical phenotype are essential to achieve a better understanding of the carcinogenesis and aggres-
siveness of cSCC. 
Our experiments reveal that some miRNAs, whose expression is described to be different in cSCCs by several 
authors, are possible key players in this cancer type and detectable by various methods. Uniform conditions 
could help to assess the relevance of miRNAs whose expression is differentially described. However, the clar-
ification of the specific miRNA expression in different cSCCs could provide key information to understand the 
evolution of cSCCs and will ultimately enable us to develop novel potential for treatment of these cancers.  
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Table 1. Summary of the analysed miRNAs and results of their regulation compared to the findings of other 
groups. Different findings are highlighted in bold letters. 
miRNA Dziunycz et al. 2010 Xu et al. 2012 presented study 
let-7a-5p not analysed slight downregulation b no different regulation 
let-7b-5p not analysed slight downregulation b no different regulation 
miR17-5p not analysed no different regulation no different regulation 
miR21-5p upregulation upregulation upregulation 
miR31-5p not analysed upregulation upregulation 
miR34a-5p not analysed no different regulation no different regulation 
miR106a-5p not analysed not analysed no different regulation 
miR155-5p not analysed no different regulation no different regulation 
miR184 upregulation a no different regulation b not detectable 
miR203 downregulation a no different regulation no different regulation 
miR205-5p no different regulation a no different regulation b upregulation 
miR206 not analysed no different regulation b not detectable 
 
a It is not mentioned whether only tumour-specific lymphocyte-reduced / -free parts of the tumour or the 
complete tumour are isolated. Normalization was only performed to U18. 
b Xu et al. investigated the complete tumour material by the multiplex RT TaqMan MicroRNA Low Density 
Array (TLDA) (Applied Biosystems) 
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Supplementary Material 
 
Experimental Design. Cutaneous SCC samples were selected from 9 anonymous immunocompetent 
individuals without inherited cancer predisposition from the Dermatology Department of Basel. Total RNA 
from cSCC as well as from anonymous healthy controls was isolated using the RecoverAll™ Total Nucleic Acid 
Isolation Kit for FFPE (Ambion) according to the manufacturers‘ instructions. The quantification of 12 specific 
miRNAs was performed in triplicates by TaqMan® MicroRNA assays (LifeTechnologies) according to the 
manufacturer‘s protocol. 
Investigation of all cSCCs for the presence of human papillomavirus (HPV) was done by polymerase chain 
reaction as described before (1). 
 
Statistical analysis. Relative miRNA expression was determined using the 2-ΔΔcT-method (2). Each examined 
miRNA was normalized against every analysed snoRNA. Fold induction was obtained for significantly 
expressed miRNAs by the difference of the normalized mean expression between cSCCs and controls. To 
exclude possible artifacts due to the regulation of the normalization genes we confirmed the results by using 
qbasePLUS© (Biogazelle), which applies the mean expression value for normalization (3). It also performs the 
necessary statistical analyses e.g. the unpaired t-test and multiple testing correction. The reference target 
stability was proven by qbase Plus©. The snoRNAs U24 and U48 emerged to be the most stable reference 
genes in our study (M < 0.7) whereas the U18 and U44 were less stable (M < 1.0). This finding correlates with 
the different results which we obtained for the normalization of several miRNA (see Fig. S3). 
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Fig. S1. Level of miR-21-5p, miR-31-5p, and miR-205-5p in control skin and in cSCC was determined by qPCR 
and normalized to U18 (a), U24 (b), U44 (c), and U48 (d) resulting in variable significances. The mean is 
indicated by the horizontal line. *P<0.05, **p<0.01, ***p<0.0001 
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Fig. S2. (A) N-fold induction of miR-21-5p, miR-31-5p, and miR205-5p in cSCC vs. control skin. Difference of 
specific miRNA expression between cSCC and control skin was determined for each normalization resulting in 
variable data. Each miRNA was normalized to all snoRNAs resulting in variable significances. The red line 
marks the value 1. (B, C) Data analysis was additionally performed by qbase PLUS (BioGazelle), which 
identified the U44 to be not valuable for normalization. Results also showed significant upregulation for the 
three miRNAs, whereby the high SD points to the variability of the cSCCs.  
 
 
4 
 
 
Fig. S3. Expression levels of four miRNAs, which show a significant increase (miR-17-5p, 106a-5p, and 155-5p) 
or decrease (let-7b-5p) only when normalized against U24 and/or U48. The mean is shown by the horizontal 
line.  
 
 
 
Table S1. Means of 2-ΔcT of all investigated miRNAs normalized against four snoRNAs from cSCC and from 
control skin. 
miRNA normalization to 
mean 2-ΔcT ±SEM p value  
(unpaired t-test) 
-fold 
change cSCC control skin 
let-7a-5p 
U18 0.794 ±0.1735 1.094 ±0.2541 0.3503 0.77 
U24 4.443 ±0.9840 4.489 ±0.5382 0.9669 0.86 
U44 1.049 ±0.2344 2.226 ±0.5200 0.0608 0.46 
U48 1.280 ±0.2558 1.346 ±0.2171 0.8458 0.84 
let-7b-5p 
U18 2.145 ±0.4340 2.598 ±0.7448 0.6145 1.02 
U24 11.58 ±2.017 10.95 ±2.193 0.8376 1.13 
U44 2.698 ±0.4055 4.792 ±0.8039 0.0361 0.60 
U48 3.177 ±0.4418 3.252 ±0.5512 0.9179 1.10 
miR17-5p 
U18 0.2608 ±0.0482 0.1989 ±0.06639 0.4671 1.71 
U24 1.440 ± 0.2738 0.6836 ±0.09524 0.0138 1.91 
U44 0.3123 ±0.0592 0.3357 ±0.08091 0.8205 1.01 
U48 0.4137 ±0.0854 0.2051 ±0.04091 0.0351 1.86 
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miR21-5p 
U18 1.572 ±0.3152 0.2061 ±0.05996 0.0003 10.88 
U24 8.948 ±1.621 0.8490 ±0.1770 <0.0001 12.09 
U44 2.146 ±0.4178 0.4570 ±0.1282 0.0007 6.44 
U48 2.377 ±0.3892 0.2623 ±0.05677 <0.0001 11.79 
miR31-5p 
U18 1.022 ±0.3810 0.02534±0.008654 0.0128 43.57 
U24 5.458 ±1.916 0.09863 ±0.02964 0.0084 48.43 
U44 1.193 ±0.3079 0.05289 ±0.01891 0.0010 25.79 
U48 1.358±0.3812 0.03651 ±0.01389 0.0017 47.22 
miR34a-5p 
U18 0.0933 ±0.01846 0.0711 ±0.01776 0.3977 1.50 
U24 0.5742 ±0.1229 0.3037 ±0.05490 0.0518 1.67 
U44 0.1498 ±0.04625 0.1561 ±0.04227 0.9211 0.89 
U48 0.1432 ±0.04089 0.09516 ±0.02133 0.2981 1.45 
miR106a-5p 
U18 0.2910 ±0.06611 0.2528 ± 0.1075 0.7713 1.54 
U24 1.613 ± 0.3614 0.8046 ±0.1280 0.0413 1.72 
U44 0.3135 ±0.04994 0.4096 ±0.1231 0.4939 0.91 
U48 0.4238 ±0.07578 0.2432 ±0.05739 0.0674 1.67 
miR155-5p 
U18 0.07741 ±0.01736 0.05424 ±0.01922 0.3857 2.33 
U24 0.4723 ±0.1259 0.2041 ±0.03841 0.0472 2.59 
U44 0.1406 ±0.05500 0.1166 ±0.04345 0.7330 1.38 
U48 0.1392 ±0.04799 0.06527 ±0.01651 0.1333 2.52 
miR184 
U18 0.000237 ±0.00015 0.000170 ±0.0000836 0.6962 0.45 
U24 0.00155 ±0.00099 0.000693 ±0.000279 0.3970 0.50 
U44 0.000463 ±0.00030 0.000262±0.0000781 0.5085 0.26 
U48 0.000511 ±0.00046 0.000157 ±0.0000413 0.3732 0.48 
miR203 
U18 3.140 ±1.511 2.259 ±0.8971 0.6142 1.28 
U24 16.01 ±7.967 8.328 ±1.929 0.3393 1.42 
U44 2.934 ±0.8228 3.552 ±0.9020 0.6209 0.76 
U48 3.974 ±1.233 2.350 ±0.5339 0.2269 1.38 
miR205-5p 
U18 5.302 ±1.189 2.115 ±0.5690 0.0222 3.17 
U24 28.44 ±6.465 10.95 ±2.491 0.0170 3.52 
U44 5.846 ±1.036 5.212 ±1.237 0.6885 1.87 
U48 7.613 ±1.495 3.449 ±0.6949 0.0174 3.43 
miR206 
U18 0.000204 ±0.000068 0.000458 ±0.000127 0.1024 0.44 
U24 0.001294 ±0.000504 0.001959 ±0.000540 0.3815 0.49 
U44 0.000497 ±0.000275 0.000905 ±0.000297 0.3019 0.26 
U48 0.000382 ±0.000124 0.000536 ±0.000138 0.4209 0.48 
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